SCHEMBL2279657

SCHEMBL2279657

COCCOC(=O)Nc1cccc(/C=C/C(=O)c2c(O)c3ccccc3[nH]c2=O)c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.51
NPC1 O15118 6/20 0.51
KMT2A Q03164 8/20 0.50
MEN1 O00255 7/20 0.50
EGFR P00533 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.46
PADI4 Q9UM07 4/20 0.45
KDM4E B2RXH2 6/20 0.44
HSD17B10 Q99714 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NLRP3 Q96P20 1/20 0.44
ASAH1 Q13510 1/20 0.43
HTT P42858 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
XBP1 P17861 1/20 0.42
POLB P06746 1/20 0.41
PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2279659 1.00 RAB9A (0.51) RAB9ANPC1KMT2AMEN1EGFR
SCHEMBL2277552 0.86 RAB9A (0.51) RAB9ANPC1KMT2AMEN1EGFR
SCHEMBL2277561 0.86 RAB9A (0.51) RAB9ANPC1KMT2AMEN1EGFR
SCHEMBL3528531 0.82 NQO1 (0.54) RAB9AKMT2AMEN1KDM4EHTT
SCHEMBL3528533 0.82 NQO1 (0.54) RAB9AKMT2AMEN1KDM4EHTT
SCHEMBL2277535 0.80 MEN1 (0.49) RAB9ANPC1KMT2AMEN1PADI4
SCHEMBL2277539 0.80 MEN1 (0.49) RAB9ANPC1KMT2AMEN1PADI4
SCHEMBL4523899 0.77 RXFP1 (0.38) RAB9ANPC1KMT2AMEN1EGFR
SCHEMBL4523900 0.77 RXFP1 (0.38) RAB9ANPC1KMT2AMEN1EGFR
SCHEMBL2280459 0.77 RAB9A (0.48) RAB9ANPC1KMT2AMEN1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 RAB9A 3791/4885NPC1 1610/4885KMT2A 3569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.